NFKB1 and ovarian carcinoma: Bortezomib is a known inhibitor of the NF-κB signaling pathway, and the activation of NF-κB was shown to suppress autophagy.35 If this is the case, then bortezomib should activate autophagy and eliminate p62.23 However, bortezomib inhibited the NF-κB signaling pathway in seven ovarian cancer lines by increasing IκB phosphorylation, but also increased p62 levels in eight ovarian cancer cells (Supplementary Figure 3).